Compare GRI & HTCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRI | HTCR |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | Japan |
| Employees | N/A | 44 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.4M |
| IPO Year | 2020 | 2022 |
| Metric | GRI | HTCR |
|---|---|---|
| Price | $2.18 | $2.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $160.00 | N/A |
| AVG Volume (30 Days) | 34.1K | ★ 55.9K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 87.84% |
| EPS Growth | N/A | ★ 414.29 |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $30,407,229.00 |
| Revenue This Year | N/A | $123.26 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $12.23 |
| Revenue Growth | N/A | ★ 39.19 |
| 52 Week Low | $0.18 | $0.15 |
| 52 Week High | $6.70 | $3.97 |
| Indicator | GRI | HTCR |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 48.19 |
| Support Level | $2.12 | $0.29 |
| Resistance Level | $2.23 | $3.85 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 51.16 | 10.00 |
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
HeartCore Enterprises Inc is a software development company providing solutions for digital transformation (DX). It develops, sells, and maintains CMS and CXM platforms using digital marketing technology, RPA, process mining solutions, myInvenio and Apromore, task mining solution CONTROLIO, and 3D-VR services including Matterport and VR360. The company also provides management consulting, education, services, and support to help customers succeed with the CXM Platform. It operates through two business units, the CX division for customer experience management and the DX division for digital transformation, which provides robotics process automation, process mining, and task mining. Its products include VR360, myInvenio, Apromore, and others, with maximum revenue from the United States.